The new facility will enable the company to introduce transition metal catalyst-screening technology to their existing manufacturing platform.
Shanghai/China — STA Pharmaceutical has recently announced its plans to launch a new transition metal catalysis center at their integrated API process, R&D and manufacturing site in Changzhou, China. The new state-of-the-art facility will allow the company to carry out rapid screening of metal catalysts, ligands, bases, acids, chemical resolving reagents, and amide formation coupling reagents, etc.
The screening kits will enable high-throughput screening of metal catalysts and ligands for C-C, C-N, C-O and C-S formation reactions, as well as many other types of reactions such as chemical resolution and amide formation. The technology allows the STA team to work effectively in finding the optimal catalysts by using a parallel interactive testing approach.
A team of scientists specialized in this technology are currently being trained at the company’s R&D center in Shanghai and once the new center becomes fully operational they will move to the Changzhou site.